Plasma proteins, including coagulation factors

Bowen, D. 2002. Haemophilia a and haemophilia b: molecular insights. Journal of Clinical Pathology - Molecular Pathology 55(1), 1-18.

Chuang, V.T., Kragh-Hansen, U., and Otagiri, M. 2002. Pharmaceutical strategies utilizing recombinant human serum albumin. Pharmaceutical Research 19(5), 569-577.

Cervenakova, L., Brown, P., Hammond, D.J., Lee, C.A., and Saenko, E.L. 2002. Factor VIII and transmissible spongiform encephalopathy: the case for safety. Haemophilia 8(2), 63-75.

DeLoughrey, T. 2006. Management of bleeding emergencies: when to use recombinant activated factor VII. Expert Opinion on Pharmacotherapy 7(1), 25-34.

Farrugia, A. 2004. Safety and supply of haemophilia products: worldwide perspectives. Haemophilia 10 (4), 327-333.

Federici, A. and Mannucci, P. 2002. Advances in the genetics and treatment of von Willebrand disease. Current Opinion in Pediatrics 14(1), 23-33.

Giangrande, P. 2005. Haemophila B: Christmas disease. Expert Opinion on Pharmacotherapy 6(9), 1517-1524.

Graw, J., Brackmann, H.H., Oldenburg, J., Schneppenheim, R., Spannagl, M., and Schwaab, R. 2005. Haemophilia A: from mutation analysis to new therapies. Nature Reviews Genetics 6(6), 488-501.

Kingdon, H. and Lundblad, R. 2002. An adventure in biotechnology: the development of haemophilia A therapeutics - from whole blood transfusion to recombinant DNA technology to gene therapy. Biotechnology and Applied Biochemistry 35, 141-148.

Klinge, J., Ananyeva, N.M., Hauser, C.A., and Saenko, E.L. 2002. Hemophilia A - from basic science to clinical practice. Seminiars in Thrombosis and Hemostasis 28(3), 309-321.

Legaz, M.E., Schmer, G., Counts, R.B., and Davie, E.W. 1973. Isolation and characterization of human factor VIII (antihaemophilic factor). Journal of Biological Chemistry 248, 3946-3955.

Nicholson, J.P., Wolmarans, M.R., and Park, G.R. 2000. The role of albumin in critical illness. British Journal of Anaesthesia 85(4), 599-610.

Ogden, J. 1992. Recombinant haemoglobin in the development of red blood cell substitutes. Trends in Biotechnology 10, 91-95.

Winslow, R. 2000. Blood substitutes: refocusing an elusive goal. British Journal of Haematology 111(2), 387-396.

Anticoagulants and related substances

Bates, S. and Weitz, J. 2GG5. New anticoagulants: beyond heparin, low molecular weight heparin and warfarin. British Journal of Pharmacology 144 (8), 1G17-1G28.

Dahlback, A. and Villotreix, B. 2GG5. The anticoagulant protein C pathway. FEBS Letters 579(15), 331G-3316.

De Kort, M., Buijsman, R.C., and van Boeckel, C.A. 2GG5. Synthetic heparin derivatives as new anticoagulant drugs. Drug Discovery Today 10(11), 769-779.

Dodt, J. 1995. Anti-coagulatory substances of bloodsucking animals: from hirudin to hirudin mimetics. Angewandte Chemie International Edition in English 34, 867-88G.

Eldor, A., Orevi, M., and Rigbi, M. 1996. The role of the leech in medical therapeutics. Blood Reviews 10(4), 2G1-2G9.

Fischer, K. 2GG4. The role of recombinant hirudins in the management of thrombotic disorders. Biodrugs 18(4), 235-268.

Linkins, L. and Weitz, J. 2GG5. New anticoagulant therapy. Annual Review of Medicine 56, 63-77.

O'Brien, L.A., Gupta, A., and Grinnell, B.W. 2GG6. Activated protein C and sepsis. Frontiers in Bioscience 11, 676-698.

Pineo, G. and Hull, R. 1997. Low molecular weight heparin-prophylaxis and treatment of venous thromboembolism. Annual Review of Medicine 48, 79-91.

Salzet, M. 2002. Leech thrombin inhibitors. Current Pharmaceutical Design 8(7), 493-503.

Sohn, J.H., Kang, H.A., Rao, K.J., Kim, C.H., Choi, E.S., Chung, B.H., and Rhee, S.K. 2001. Current status of the anticoagulant hirudin: its biotechnological production and clinical practice. Applied Microbiology and Biotechnology 57(5-6), 606-613.

Walker, C. and Royston, D. 2002. Thrombin generation and its inhibition: a review of the scientific basis and mechanism of action of anticoagulant therapies. British Journal of anaesthesia 88(6), 848-863.


Al-Buhairi, A. and Jan, M. 2002. Recombinant tissue plasminogen activator for acute ischemic stroke. Saudi Medical Journal 23(1), 13-19.

Banerjee, A., Chisti, Y., and Banerjee, U.C. 2004. Streptokinase - a clinically useful thrombolytic agent. Biotechnology Advances 22(4), 287-307.

Bansal, V. and Roychoudhury, P. 2006. Production and purification of urokinase: a comprehensive review. Protein Expression and Purification 45(1), 1-14.

Blasi, F. 1999. The urokinase receptor. A cell surface, regulated chemokine. APMIS 107(1), 96-101.

Castillo, P.A., Palmer, C.S., Halpern, M.T., Hatziandreu, E.J., and Gersh, B.J. 1997. Cost-effectiveness of thrombolytic therapy for acute myocardial infarction. Annals of Pharmacotherapy 31(5), 596-603.

Collen, D. 1998. Staphylokinase: a potent, uniquely fibrin-selective thrombolytic agent. Nature Medicine 4(3), 279-284.

Gillis, J.C., Wagstaff, A.J., and Goa, K.L. 1995. Alteplase. A reappraisal of its pharmacological properties and therapeutic use in acute myocardial infarction. Drugs 50(1), 102-136.

Marder, V. and Stewart, D. 2002. Towards safer thrombolytic therapy. Seminars in Haematology 39(3), 206216.

Peng, Y., Yang, X., and Zhang, Y. 2005. Microbial fibrinolytic enzymes: an overview of source, production, properties and thrombolytic activity in vivo. Applied Microbiology and Biotechnology 69(2), 126-132.

Perler, B. 2005. Thrombolytic therapeutics: the current state of affairs. Journal of Endovascular Therapy 12(2), 224-232.

Preissner, K.T., Kanse, S.M., and May, A.E. 2000. Urokinase receptor: a molecular organizer in cellular communication. Current Opinion in Cell Biology 12(5), 621-628.

Rabasseda, X. 2001. Tenecteplase (TNK tissue plasminogen activator): a new fibrinolytic for the acute treatment of myocardial infarction. Drugs of Today 37(11), 749-760.

Verstraete, M. 2000. Third generation thrombolytic drugs. American Journal of Medicine 109 (1), 52-58.

Enzyme therapeutics

Avramis, V. and Panosyan, E. 2005. Pharmacokinetic/pharmacodynamic relationships of asparaginase formulations - the past, the present and recommendations for the future. Clinical Pharmacokinetics 44(4), 367-393.

Barranger, J.A., Tomich, J., Weiler, S., Sakallah, S., Sansieri, C., Mifflin, T., Bahnson, A., Wei, F.S., Wei, J.F., Vallor, M., Nimgaonkar, M., Ball, E., Mohney, T., Dunigan., J., Ohashi, T., Bansal, V., Mannion Henderson, J., Liu, C.M., and Rice, E. 1995. Molecular biology of glucocerebrosidase and the treatment of Gaucher disease. Cytokines and Molecular Therapy 1(3), 149-163. Chakrabarti, R. and Schuster, S. 1997. L-Asparaginase - perspectives on the mechanisms of action and resistance. International Journal of Pediatric Haematology/Oncology 4(6), 597-611.

Chapple, L. 1997. Reactive oxygen species and antioxidants in inflammatory diseases. Journal of Clinical Peri-odontology 24(5), 287-296.

Conway, S. and Watson, A. 1997. Nebulized bronchodilators, corticosteroids and rhDNase in adult patients with cystic fibrosis. Thorax 52(2), S64-S68.

Grabowski, G. 2005. Recent clinical progress in Gaucher disease. Current Opinion in Pediatrics 17(4), 519524.

James, E. 1994. Superoxide dismutase. Parasitology Today 10(12), 482-484.

Ronghe, M., Burke, G.A., Lowis, S.P., and Estlin, E.J. 2001. Remission induction therapy for childhood acute lymphoblastic leukaemia: clinical and cellular pharmacology of vincristine, corticosteroids, L-asparaginase and anthracyclines. Cancer Treatment Reviews 27(6), 327-337.

Zhao, H. and Grabowski. G. 2002. Gaucher disease: perspectives on a prototype lysosomal disease. Cellular and Molecular Life Sciences 59(4), 694-707.

Your Heart and Nutrition

Your Heart and Nutrition

Prevention is better than a cure. Learn how to cherish your heart by taking the necessary means to keep it pumping healthily and steadily through your life.

Get My Free Ebook

Post a comment